MX2021011688A - Combinaciones utiles en un metodo para tratar sarcoma. - Google Patents

Combinaciones utiles en un metodo para tratar sarcoma.

Info

Publication number
MX2021011688A
MX2021011688A MX2021011688A MX2021011688A MX2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A MX 2021011688 A MX2021011688 A MX 2021011688A
Authority
MX
Mexico
Prior art keywords
treating sarcoma
subject
useful combinations
sarcoma
treating
Prior art date
Application number
MX2021011688A
Other languages
English (en)
Spanish (es)
Inventor
Marla L Weetall
Liangxian Cao
Josephine Sheedy
Robert Spiegel
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of MX2021011688A publication Critical patent/MX2021011688A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2021011688A 2019-03-27 2020-03-27 Combinaciones utiles en un metodo para tratar sarcoma. MX2021011688A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962825017P 2019-03-27 2019-03-27
PCT/US2020/025532 WO2020198705A1 (en) 2019-03-27 2020-03-27 Combinations useful in a method for treating sarcoma

Publications (1)

Publication Number Publication Date
MX2021011688A true MX2021011688A (es) 2022-01-24

Family

ID=72609016

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011688A MX2021011688A (es) 2019-03-27 2020-03-27 Combinaciones utiles en un metodo para tratar sarcoma.

Country Status (11)

Country Link
US (1) US20220152024A1 (enExample)
EP (1) EP3947379A4 (enExample)
JP (1) JP7602481B2 (enExample)
CN (1) CN114096537B (enExample)
AU (1) AU2020248103A1 (enExample)
BR (1) BR112021019170A2 (enExample)
CA (1) CA3134648A1 (enExample)
EA (1) EA202192349A1 (enExample)
IL (1) IL286647A (enExample)
MX (1) MX2021011688A (enExample)
WO (1) WO2020198705A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
KR20090094148A (ko) * 2006-12-20 2009-09-03 제이-씨 헬쓰 케어 리미티드 페길화 리포좀 독소루비신의 투여 방법
PH12015501130B1 (en) * 2012-11-21 2023-01-27 Ptc Therapeutics Inc Substituted reverse pyrimidine bmi-1 inhibitors
JP2021535198A (ja) * 2018-08-17 2021-12-16 ピーティーシー セラピューティクス, インコーポレイテッド 膵臓癌を治療する方法
KR20210151061A (ko) * 2019-03-11 2021-12-13 피티씨 테라퓨틱스, 인크. 향상된 생체이용률을 갖는 화합물 형태 및 이의 제형

Also Published As

Publication number Publication date
CA3134648A1 (en) 2020-10-01
EP3947379A4 (en) 2022-12-21
CN114096537B (zh) 2025-01-10
BR112021019170A2 (pt) 2022-03-03
CN114096537A (zh) 2022-02-25
EP3947379A1 (en) 2022-02-09
JP2022519930A (ja) 2022-03-25
IL286647A (en) 2021-10-31
WO2020198705A1 (en) 2020-10-01
JP7602481B2 (ja) 2024-12-18
AU2020248103A1 (en) 2021-10-21
EA202192349A1 (ru) 2022-02-01
US20220152024A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
MX2022014548A (es) Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
MX386500B (es) Anticuerpos contra icos
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
CL2017000507A1 (es) Derivados de benzodiazepina citotóxicos
CL2020003276A1 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
MX2022003689A (es) Metodos y composiciones para el tratamiento contra una enfermedad o trastorno.
CL2019002340A1 (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc1.
MX389692B (es) Composiciones y métodos para promover el crecimiento del cabello con inhibidores de mpc.
CL2019002797A1 (es) Preservantes para madera.
MX389499B (es) Metodos, composiciones y usos relacionados con los mismos
EA201792096A3 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2019003545A (es) Compuestos heterociclicos y uso de los mismos para prevenir o tratar infecciones bacterianas.
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
CO2021000087A2 (es) Combinación de factor vii y de un anticuerpo biespecífico dirigido contra los factores ix y x
GB2543709A (en) Pharmaceutical agent
MX2016002308A (es) Tratamiento del mieloma multiple.
MX381429B (es) Tricostatina a (tsa) para usarse en el tratamiento del cáncer.
UY38472A (es) Moduladores de la expresión de foxp3
WO2020180842A3 (en) Aptamers and use thereof
PE20200749A1 (es) Moduladores de la expresion de enac
EA202192349A1 (ru) Комбинации, пригодные в способе лечения саркомы
EA201990443A1 (ru) Новое применение n,n-бис-2 -меркаптоэтилизофталамида